Q4 2024 Earnings Forecast for Bristol-Myers Squibb (NYSE:BMY) Issued By Zacks Research

Bristol-Myers Squibb (NYSE:BMY) – Zacks Research upped their Q4 2024 earnings per share estimates for shares of Bristol-Myers Squibb in a report released on Wednesday, June 26th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will post earnings per share of $1.70 for the quarter, up from their previous estimate of $1.69. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $0.58 per share. Zacks Research also issued estimates for Bristol-Myers Squibb’s FY2026 earnings at $6.25 EPS.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period last year, the company earned $2.05 EPS. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% on a year-over-year basis.

Other research analysts have also recently issued reports about the company. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Barclays lowered their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Finally, StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 27th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Trading Down 0.6 %

Shares of NYSE:BMY opened at $41.30 on Monday. The stock has a market capitalization of $83.72 billion, a price-to-earnings ratio of -13.32, a PEG ratio of 14.21 and a beta of 0.44. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The stock’s 50-day simple moving average is $42.97 and its two-hundred day simple moving average is $48.11. Bristol-Myers Squibb has a 52-week low of $39.63 and a 52-week high of $65.38.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 5.81%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Institutional Trading of Bristol-Myers Squibb

A number of large investors have recently added to or reduced their stakes in the company. Westside Investment Management Inc. increased its stake in Bristol-Myers Squibb by 2.9% in the 4th quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock worth $367,000 after acquiring an additional 204 shares during the last quarter. Traynor Capital Management Inc. increased its position in shares of Bristol-Myers Squibb by 2.8% during the 1st quarter. Traynor Capital Management Inc. now owns 7,672 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 207 shares during the last quarter. Fulton Breakefield Broenniman LLC increased its position in shares of Bristol-Myers Squibb by 4.6% during the 4th quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 209 shares during the last quarter. Chapin Davis Inc. increased its position in shares of Bristol-Myers Squibb by 1.2% during the 4th quarter. Chapin Davis Inc. now owns 18,385 shares of the biopharmaceutical company’s stock valued at $943,000 after purchasing an additional 214 shares during the last quarter. Finally, Accurate Wealth Management LLC increased its position in shares of Bristol-Myers Squibb by 4.0% during the 1st quarter. Accurate Wealth Management LLC now owns 5,612 shares of the biopharmaceutical company’s stock valued at $304,000 after purchasing an additional 216 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.